Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Looking4Doubleson Mar 22, 2020 6:39am
83 Views
Post# 30834670

RE:If the vote passes

RE:If the vote passes
Scotty wrote: Is there a scenario where this doesn't immediately tank into oblivion? LF input!


Sure,  Here's a few:

1.) At the same time they do a reverse split, Bassa moves the company to a new stock exchange and Bassa's fund and his Israeli banker friends get to invest in the company, since it would no longer be a penny stock any more.  The added visibility on a bigger exchange at the time when all other stocks are tanking could be pretty inviting for big fund managers.  (ie Get in early on the next GW Pharma is how the company could pitch it)

2.) Due to the corona virus issue, you could see regulators loosen their testing requirements significantly for either drug in order to save more people during this time period.  In the U.S. they just did a LIVE human test for a vaccine already after a few months of testing and that broke ALL of the standard regulations rules ! (normally takes 12 months)   I don't see why they couldn't do the same for GVHD.
Bullboard Posts